Engasertib is an investigational new drug that is being evaluated by Vaderis Therapeutics for the treatment of hereditary haemorrhagic telangiectasia. It acts as a c-akt protein inhibitor.[1][2][3][4]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H25N3O3 |
| Molar mass | 415.493 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
edit- ↑ "Engasertib - Vaderis Therapeutics". AdisInsight. Springer Nature Switzerland AG.
- ↑ Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gómez Del Olmo V, et al. (November 2025). "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 393 (21): 2131–2141. doi:10.1056/NEJMoa2504411. PMID 41297007.
- ↑ Al-Samkari H, Picard D, Mager HJ (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia. Reply". The New England Journal of Medicine. 394 (8): 825–826. doi:10.1056/NEJMc2518633. PMID 41707157.
- ↑ Liang D, Lin Y, He L (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 394 (8): 825. doi:10.1056/NEJMc2518633. PMID 41707156.